Gilead Sciences Inc diskutieren

piccolo90 stimmt der Outperform-Einschätzung der institutionellen Analysten zu

Gilead has a great track record of strong free cash flow...

Regardless of the economy, patients with critical illnesses, such as HIV/AIDS, can't afford to stop receiving treatments. For example, there are over a million HIV-positive people in the U.S. and almost 40 million in total globally (and the numbers continue to grow). With proper drugs they can live longer, and the earlier they receive treatment, the better. As a global leading player in this field, Gilead Sciences is grabbing a big share of the expanding market for HIV/AIDS drugs and would continue doing so even when the next recession hits. Gilead Science has also been working to widen its focus to cover other critical illnesses, such as liver diseases, hematology/oncology, cardiovascular, and inflammation/respiratory diseases.

With operations in over 30 countries, Gilead Sciences has a great track record of strong free cash flow and high efficiency in capital allocation throughout various periods of an economic cycle. During the financial crisis, the company beat analysts' estimates and raised guidance, increasing annual revenue from $4,230 million in 2007 to $7,011 million in 2009 and free cash flow from $1,687 million in 2007

 to $2,850 million in 2009, while being able to keep ROIC at around 40% and ROE above 50%.

stratec stimmt am 14.01.2018 der Outperform-

Einschätzung

der institutionellen Analysten aber mit dem Kursziel 95$ zu.

kein Grund nicht einzusteigen

ohne fundamentale Veränderung bestraft man Gilead nicht so, wird schnell wieder kommen.

Biotechnologie und Medizintechnik SecteurRecherche Agenda 15/03 Detachment Dividende

phonebroker stimmt dem Sentiment von 'Buy' zu

.

SektorBiotechnologische und medizinische Forschung

• Hemlibra, die Anti-Hämophilie-Droge der Roche AG, die Anti-HIV-Behandlung von Bikarvary, Gilead Sciences Inc. und die wöchentliche Diabetes-Behandlung von Novo Nordisk werden voraussichtlich bis 2022 einen Umsatz von 3 Milliarden US-Dollar übertreffen .

Gilead Sciences Inc

Kaufen aus Intuition

Hier könnte sich ein Boden im Chart ausbilden, ich vertraue mal auf meine Intuition.